Ivermectin 'makes no clinical difference' in COVID-19: major trial

Early intervention with the much-touted drug fails to keep high-risk patients out of hospital or shorten recovery times, researchers say

High-dose ivermectin treatment of symptomatic patients early in their COVID-19 illness doesn’t reduce the risk of hospital admission, according to one of the largest randomised trials of the antiparasitic to date.

Protestors in London, UK, September 2021.

The international TOGETHER trial found no clinical advantage in using the drug.

Investigators enrolled 3500 adults with